Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria

Current Opinion in Microbiology

Volumn 8, Issue 5, 2005, Pages 510-517

  Appelbaum, Peter C ^a   Jacobs, Michael R ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTOBIPROLE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; DALBAVANCIN; DAPTOMYCIN; DK 507K; DX 619; GATIFLOXACIN; GLYCOPEPTIDE; ICLAPRIM; KETOLIDE; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; LIPOPEPTIDE; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; NAPHTHYRIDINE DERIVATIVE; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PEPTIDE DEFORMYLASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANBEZOLID; RO 639141; TAK 599; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIC 105555; WCK 1153; WCK 771; WCK 919;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG MECHANISM; ENTEROCOCCUS; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS PYOGENES; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; DRUG APPROVAL; DRUG RESISTANCE, BACTERIAL; DRUGS, INVESTIGATIONAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; STAPHYLOCOCCUS; STREPTOCOCCUS;

BACTERIA (MICROORGANISMS); POSIBACTERIA; STAPHYLOCOCCI; STAPHYLOCOCCUS;

EID: 25144517858     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2005.07.001     Document Type: Review

References (56)

1. M.R. Jacobs, S. Bajaksouzian, A. Windau, C.E. Good, G. Lin, G.A. Pankuch, and P.C. Appelbaum Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 US Surveillance Study Clin Lab Med 24 2004 503 530 Overview of antimicrobial susceptibility of Streptococcus pneumoniae based on pharmacokinetic and pharmacodynamic parameters to interpret susceptibility data in a clinically meaningful way. Of the isolates tested, >99% were susceptible to respiratory fluoroquinolones, 91.6% to amoxicillin, 92.1% to amoxicillin and clavulanic acid (95.2% at the extended-release formulation breakpoint), 90.6% to clindamycin, 80.4% to doxycycline, 71.0% to azithromycin, 72.3% to clarithromycin, 71.8% to cefprozil and cefdinir, 72.6% to cefuroxime axetil, 66.3% to cexime, 63.7% to trimethoprim-sulfamethoxazole, and 19.7% to cefaclor.
2. M.R. Jacobs, D. Felmingham, P.C. Appelbaum, and R.N. Gruneberg The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents J Antimicrob Chemother 52 2003 229 246
3. P.R. Hsueh, L.J. Teng, C.M. Lee, W.K. Huang, T.L. Wu, J.H. Wan, D. Yang, J.M. Shyr, Y.C. Chuang, and J.J. Yan Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data Antimicrob Agents Chemother 47 2003 2152 2157
4. D.J. Diekema, M.A. Pfaller, F.J. Schmitz, J. Smayevsky, J. Bell, R.N. Jones, and M. Beach Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999 Clin Infect Dis 32 2001 S114 S132
5. E. Palavecino Community-acquired methicillin-resistant Staphylococcus aureus infections Clin Lab Med 24 2004 403 418 Community-acquired methicillin-resistant Staphylococcus aureus infections have recently been documented in many countries among healthy individuals that have no recognizable risk factors. These community-acquired strains are highly virulent and are epidemiologically and clonally unrelated to hospital-acquired strains.
6. T.R. Fritsche, H.S. Sader, and R.N. Jones Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002) Diagn Microbiol Infect Dis 47 2003 435 440
7. H.B. Kim, H.C. Jang, H.J. Nam, Y.S. Lee, B.S. Kim, W.B. Park, K.D. Lee, Y.J. Choi, S.W. Park, and M.D. Oh In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey Antimicrob Agents Chemother 48 2004 1124 1127
8. P.C. Appelbaum, and B. Bozdogan Vancomycin resistance in Staphylococcus aureus Clin Lab Med 24 2004 381 402 Vancomycin resistance in enterococci, predominantly Enterococcus faecium, developed in the latter half of the 1980s; the long-anticipated development of vancomycin resistance in Staphylococcus aureus has now occurred in three patients in the US. In 2002, two patients with vancomycin-resistant S. aureus infections were documented, with a third patient in 2003. In one instance, the patient had skin lesions co-infected with a vancomycin-resistant E. faecalis, and both species contained the same vanA resistance gene.
9. W.C. Noble, Z. Virani, and R.G. Cree Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus FEMS Microbiol Lett 72 1992 195 198
10. A.H. Mutnick, D.J. Biedenbach, J.D. Turnidge, and R.N. Jones Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000 Diagn Microbiol Infect Dis 43 2002 65 73
11. P. Hebeisen, I. Heinze-Krauss, P. Angehrn, P. Hohl, M.G. Page, and R.L. Then In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci Antimicrob Agents Chemother 45 2001 825 836
12. Sader HS, Deshpande LM, Jones RN: Antimicrobial activity and spectrum of PPI-0903 (TAK-599), a novel cephalosporin, tested against a worldwide collection of clinical strains. Abstract F-325. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004.
13. S. Murphy, and R.J. Pinney Teicoplanin or vancomycin in the treatment of Gram-positive infections? J Clin Pharm Ther 20 1995 5 11
14. G. Candiani, M. Abbondi, M. Borgonovi, G. Romano, and F. Parenti In vitro and in vivo antibacterial activity of BI 397 [dalbavancin], a new semi-synthetic glycopeptide antibiotic J Antimicrob Chemother 44 1999 179 192
15. A. Tanitame, Y. Oyamada, K. Ofuji, M. Fujimoto, K. Suzuki, T. Ueda, H. Terauchi, M. Kawasaki, K. Nagai, M. Wachi, and J. Yamagishi Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring Bioorg Med Chem 12 2004 5515 5524
16. A. Tanitame, Y. Oyamada, K. Ofuji, M. Fujimoto, N. Iwai, Y. Hiyama, K. Suzuki, H. Ito, H. Terauchi, and M. Kawasaki Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives J Med Chem 47 2004 3693 3696
17. H. Inagaki, H. Takahashi, and M. Takemura Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline- 3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4. 3. 0]nonan-8-yl substituents at the C-7 position Bioorg Med Chem Lett 14 2004 5193 5198
18. M.R. Jacobs, S. Bajaksouzian, A. Windau, P.C. Appelbaum, M.V. Patel, S.V. Gupte, S.S. Bhagwat, N.J. De Souza, and H.F. Khorakiwala In vitro activity of the new quinolone WCK 771 against staphylococci Antimicrob Agents Chemother 48 2004 3338 3342
19. Pankuch GA, Jacobs MR, Khorakiwala H, De Souza N, Patel M, Appelbaum PC: Antipneumococcal activities of WCK 771A and WCK 919 (two new quinolones) compared to 12 other agents against 177 quinolone-susceptible pneumococci. Abstract F-541. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001.
20. Hoellman DB, Kelly LM, Smith KA, Bozdogan B, Jacobs MR, Appelbaum PC: Antistaphylococcal activity of DX-619 (including against a VRSA strain) compared to eleven other agents. Abstract F-1056. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003.
21. T. Otani, M. Tanaka, E. Ito, Y. Kurosaka, Y. Murakami, K. Onodera, T. Akasaka, and K. Sato In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone Antimicrob Agents Chemother 47 2003 3750 3759
22. A.M. Nilius, L.L. Shen, D. Hensey-Rudloff, L.S. Almer, J.M. Beyer, D.J. Balli, Y. Cai, and R.K. Flamm In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone Antimicrob Agents Chemother 47 2003 3260 3269
23. G. Ackermann, and A.C. Rodloff Drugs of the 21st century: telithromycin (HMR 3647) - the first ketolide J Antimicrob Chemother 51 2003 497 511
24. C.M. Fogarty, S. Kohno, P. Buchanan, M. Aubier, and M. Baz Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin J Antimicrob Chemother 51 2003 947 955
25. Johnson B, Stevens T, Bouchillon S, Johnson J, Hoban DJ, Hackel M, Person M, Dowzicky M: Tigecycline evaluation surveillance trial (T.E.S.T.): in vitro antibacterial activity against methicillin resistant and methicillin sensitive Staphylococcus aureus isolates. Abstract E-2061. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004.
26. D. Milatovic, F.J. Schmitz, J. Verhoef, and A.C. Fluit Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates Antimicrob Agents Chemother 47 2003 400 404
27. Park C, Blais J, Lopez S, Gomez M, Rossi R, Candiani G, Jabes D, Kubo A, Maniar M, Margolis P et al.: VIC-105555, a new lincosamide with improved in vivo efficacy and good in vitro activity. Abstract F-1392. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004.
28. Blais J, Park C, Maniar M, Margolis P, Rafanan N, Kubo A, Lopez S, Gomez M, Hackbarth C, Lewis J et al.: Bactericidal activity, postantibiotic effect and frequency of resistance of the novel lincosamide VIC-105555. Abstract F-1391. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004.
29. Tembe V, Chen D, Scott L, Mukadam S, Withers G, Yuan Z, Lewis M, Gordeev M, Buckwalter M, Dowell J et al.: Improved pharmacokinetics of VIC-105555: long half-life and large volume of distribution in multiple species. Abstract F-1395. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2004.
30. P.W. Ament, N. Jamshed, and J.P. Horne Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections Am Fam Physician 65 2002 663 670
31. D.B. Hoellman, G. Lin, L.M. Ednie, A. Rattan, M.R. Jacobs, and P.C. Appelbaum Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents Antimicrob Agents Chemother 47 2003 1148 1150
32. J.P. Manzella Quinupristin-dalfopristin: a new antibiotic for severe Gram-positive infections Am Fam Physician 64 2001 1863 1866
33. C.F. Carpenter, and H.F. Chambers Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens Clin Infect Dis 38 2004 994 1000
34. E.S. Schweiger, and J.M. Weinberg Novel antibacterial agents for skin and skin structure infections J Am Acad Dermatol 50 2004 331 340
35. P. Schneider, S. Hawser, and K. Islam Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria Bioorg Med Chem Lett 13 2003 4217 4221
36. Jacobs MR, Bajaksouzian S, Windau A, Appelbaum PC: BAL9141, the active component of prodrug BAL5788: activity against Staphylococci and Pneumococci by microdilution and E-test methods. Abstract D-1920. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004.
37. Jacobs MR, Bajaksouzian S, Windau A, Good CE, Patel MV, De Souza N, Khorakiwala H, Appelbaum PC: Activity of WCK 1152 and WCK 1153, novel quinolone compounds. Activity against Streptococcus pneumoniae. Abstract F-436. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003.
38. Jacobs MR, Good CE, Windau A, Bajaksouzian S, Patel MV, De Souza N, Khorakiwala H, Appelbaum PC: Activity of WCK-1152 and WCK-1153, novel quinolone compounds, activity against Staphylococci. Abstract F-435. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003.
39. P.R. Hsueh, L.J. Teng, T.L. Wu, D. Yang, W.K. Huang, J.M. Shyr, Y.C. Chuang, J.H. Wan, J.J. Yan, and J.J. Lu Telithromycin- and fluoroquinolone- resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data Antimicrob Agents Chemother 47 2003 2145 2151
40. F.J. Schmitz, J. Petridou, D. Milatovic, J. Verhoef, A.C. Fluit, and S. Schwarz In vitro activity of new ketolides against macrolide-susceptible and -resistant Staphylococcus aureus isolates with defined resistance gene status J Antimicrob Chemother 49 2002 580 582
41. I.A. Critchley, D.C. Draghi, D.F. Sahm, C. Thornsberry, M.E. Jones, and J.A. Karlowsky Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001 J Antimicrob Chemother 51 2003 639 649
42. F. Garcia-Garrote, E. Cercenado, L. Alcala, and E. Bouza In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates Antimicrob Agents Chemother 42 1998 2452 2455
43. G. Lin, K. Credito, L.M. Ednie, and P.C. Appelbaum Antistaphylococcal activity of dalbavancin, an experimentql glycopeptide Antimicrob Agents Chemother 49 2005 770 772
44. J.M. Streit, T.R. Fritsche, H.S. Sader, and R.N. Jones Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates Diagn Microbiol Infect Dis 48 2004 137 143
45. P. Bemer, M.E. Juvin, A. Bryskier, and H. Drugeon In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant Gram-positive isolates Antimicrob Agents Chemother 47 2003 3025 3029
46. Good CE, Windau A, Bajaksouzian S, Jacobs MR, Appelbaum PC: AR-100, a novel diaminopyrimidine compound: activity against Streptococci. Abstract F-2023. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002.
47. Bajaksouzian S, Windau A, Appelbaum PC, Jacobs MR: AR-100, a novel diaminopyrimidine compound: activity against Staphylococci and Enterococci. Abstract F-2024. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002.
48. Bell JM, Turnidge JD, Inoue M, Kohno S, Hirakata Y, Ono Y: Activity of a peptide deformylase inhititor (NV PDF-713) against isolates from Japan. Abstract E-2049. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004.
49. L.M. Ednie, G. Pankuch, and P.C. Appelbaum Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents Antimicrob Agents Chemother 48 2004 4027 4032
50. K. Credito, G. Lin, L.M. Ednie, and P.C. Appelbaum Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents Antimicrob Agents Chemother 48 2004 4033 4036
51. Inagaki H, Miyauchi RN, Itoh M, Kimura K, Chiba M, Tanaka M, Takahashi H, Takemura M, Hayakawa I: DX-619, a novel des-F(6)-quinolone: synthesis and in vitro antibacterial activity against multi-drug resistant Gram-positive bacteria. Abstract F-1054. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003.
52. Schito G, Felmingham D: Susceptibility of Streptococcus pneumoniae isolates to penicillin, azithromycin, and telithromycin. Abstract C2-829. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004.
53. F.J. Boswell, J.M. Andrews, J.P. Ashby, C. Fogarty, N.P. Brenwald, and R. Wise The in vitro activity of HMR 3647, a new ketolide antimicrobial agent J Antimicrob Chemother 42 1998 703 709
54. S.S. Richter, D.E. Kealey, C.T. Murray, K.P. Heilmann, S.L. Coffman, and G.V. Doern The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species J Antimicrob Chemother 52 2003 123 127
55. G.A. Pankuch, L.M. Kelly, G. Lin, A. Bryskier, C. Couturier, M.R. Jacobs, and P.C. Applebaum Activities of a new oral streptogram XRP 2868, compared to those of other agents against Streptococcus pneumoniae and Haemophilus species Antimicrob Agents Chemother 47 2003 3270 3274
56. G.M. Elioupoulos, M.J. Ferraro, C.B. Wennersten, and R.C. Moellering Jr. In vitro activity of an oral streptogramin antimicrobial XRP 2868, against gram-positive bacteria Antimicrob Agentc Chemother 49 2005 3034 3039